**Bio-Path Holdings, Inc. Receives Nasdaq Listing Deficiency Notice, Holds Annual Meeting**

Bio-Path Holdings, Inc. (NASDAQ: BPTH) recently disclosed in an 8-K SEC filing that the company received a notification from the Listing Qualifications Department of the Nasdaq Stock Market regarding a non-compliance issue. The notice highlighted that Bio-Path did not meet the minimum bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market.

As per Nasdaq Listing Rule 5810(c)(3)(A), Bio-Path has been granted a 180-day window until June 10, 2025, to comply with the bid price rule. During this period, if the closing bid price of the common stock reaches or exceeds $1.00 for a minimum of ten consecutive business days, the company will receive written confirmation of compliance from Nasdaq.

If Bio-Path fails to meet the listing requirements by the given deadline and is not eligible for an extension, Nasdaq may delist the company’s common stock. In the event of a potential delisting, the company has the option to appeal the decision to a Nasdaq Hearings Panel.

To address the non-compliance issue, Bio-Path intends to closely monitor its stock price and explore available strategies, including the possibility of implementing a reverse stock split.

Moreover, Bio-Path recently conducted its 2024 Annual Meeting of Stockholders, where several significant approvals were attained. Stockholders sanctioned an amendment to the Bio-Path Holdings, Inc. 2022 Stock Incentive Plan, allowing for an increase in the total number of shares that can be issued under the plan.

Additionally, Bio-Path’s stockholders elected directors, ratified the appointment of Ernst & Young, LLP as the independent registered public accounting firm, and approved various amendments related to the company’s stock issuance, reverse stock split, and potential stock placements.

It is worth noting that while a proposal for the adjournment of the meeting was approved, it became unnecessary as Proposal Four secured adequate support.

Bio-Path Holdings, Inc. will continue to navigate the compliance process diligently and stay engaged with shareholders as it progresses towards meeting Nasdaq’s requirements.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Bio-Path’s 8K filing here.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.